We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Hybrid Liquid Biopsy Platform Enables Tracking and Monitoring of Circulating Tumor Cells

By LabMedica International staff writers
Posted on 01 Apr 2020
Print article
Image: A new fluid analyzing platform allows for the isolation of circulating tumor cells (CTCs), which are formed during metastasis (Photo courtesy of NYU Abu Dhabi)
Image: A new fluid analyzing platform allows for the isolation of circulating tumor cells (CTCs), which are formed during metastasis (Photo courtesy of NYU Abu Dhabi)
By creating a hybrid microfluidic liquid biopsy platform that incorporates atomic force microscopy (AFM), cancer researchers have captured and characterized circulating tumor cells (CTCs), a technique which should prove useful in the diagnosis and prognosis of prostate cancer as well as other forms of cancer.

Circulating tumor cells (CTCs) carried by the patient’s bloodstream are known to lead to the metastatic spread of cancer. Although they are important cancer biomarkers, CTCs are very rare and hard to isolate from the background of billions of healthy blood cells. Nonetheless, it has become clear that an understanding of the nanomechanical characteristics of CTCs, such as elasticity and adhesiveness, would be a significant advancement in tracking and monitoring cancer progression and metastasis.

To attain this understanding, investigators at NYU Dubai (New York, NY, USA and Dubai) developed a combined microfluidic-AFM platform based on specific antibody-based capture of CTCs in whole-blood samples from prostate cancer patients and subsequent characterization of their elasticity and adhesiveness. The microfluidic device was designed to provide a high density of oriented antibodies on its glass surface. The device was assembled via reversible physical polydimethylsiloxane (PDMS)-to-glass bonding, which later allowed external access to captured CTCs. The device was highly efficient in capturing prostate CTCs via antibodies directed at their epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA).

Atomic force microscopy (AFM) is a type of scanning probe microscopy (SPM), with demonstrated resolution on the order of fractions of a nanometer, more than 1000 times better than the optical diffraction limit. AFM has three major abilities: force measurement, topographic imaging, and manipulation. In force measurement, AFMs can be used to measure the forces between the microscope’s probe and the sample as a function of their mutual separation. This can be applied to measure the mechanical properties of the sample, such as the sample's Young's modulus, a measure of stiffness.

Results revealed that the hybrid biofluidic device was suitable for AFM measurements of captured intact CTCs. When nanomechanically characterized, CTCs originating from metastatic cancer demonstrated decreased elasticity and increased deformability compared to those originating from localized cancer. While the average adhesion of CTCs to the AFM tip surface remained the same in both the groups, there were fewer multiple adhesion events in metastatic CTCs than there were in their counterparts. Thus, the platform was shown to be simple, robust, and reliable and could be useful in the diagnosis and prognosis of prostate cancer as well as other forms of cancer.

"We expect that this platform could constitute a potentially very powerful tool for cancer diagnosis and prognosis, by identifying CTCs mechanical and biological phenotypes at the single cell level," said senior author Dr. Mohammad A. Qasaimeh, assistant professor of mechanical and biomedical engineering at NYU Dubai.

The liquid biopsy-AFM platform was described in the March 23, 2020, online edition of the journal Microsystems and Nanoengineering.

Related Links:
NYU Dubai

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.